nach oben

Tumor Biology

Erschienen in:

01.08.2013 | Research Article

Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer

verfasst von: Xin-yan Wang, Hai-jiao Wang, Xiu-qin Li

Erschienen in: Tumor Biology | Ausgabe 4/2013

Einloggen, um Zugang zu erhalten

Abstract

We investigated the association between peroxiredoxin III (PRX III) and chemotherapy resistance in ovarian cancer. Patient’s specimens were taken at the time of surgery. Determination of resistance is based on whether first diagnosis of relapse occurred within 6 months after the cessation of chemotherapy. PRX III expression was immunohistochemically determined in paraffin-embedded specimens from platinum-resistant (Pt-resistant) and platinum-sensitive (Pt-sensitive) patients. The Pt-resistant group had significantly higher PRX III protein compared to the Pt-sensitive group. The two groups showed no significant differences in pathological classification and age, although they differed significantly in tissue differentiation and stage. PRX III protein was significantly higher in the Pt-resistant serous carcinomas, in moderately and poorly differentiated, and in stage III and IV ovarian cancer tissues compared to the Pt-sensitive group. PRX III may be associated with drug resistance in ovarian cancer.

Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36.PubMedCrossRef

Sourbier C. Ovarian cancer: emerging molecular-targeted therapies. Biologics. 2012;6:147–54.PubMed

Davidson B, Trope CG, Reich R. Epithelial-mesenchymal transition in ovarian carcinoma. Front Oncol. 2012;2:33.PubMedCrossRef

Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3:502–16.PubMedCrossRef

NCCN. NCCN clinical practice guideline in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Fort Washington: NCCN; 2013.

Godwin AK, Meister A, O’Dwyer PJ, Huang CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA. 1992;89:3070–4.PubMedCrossRef

Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res. 1999;59:3077–83.PubMed

Yan X, Fraser M, Qiu Q, Tsang BK. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner. Gynecol Oncol. 2006;102:348–55.PubMedCrossRef

Krieger ML, Eckstein N, Schneider V, Koch M, Royer HD, Jaehde U, et al. Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm. 2010;389:10–7.PubMedCrossRef

10.

Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–79.PubMedCrossRef

11.

Masuda H, Tanaka T, Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun. 1994;203:1175–80.PubMedCrossRef

12.

Klaunig JE, Xu Y, Isenberg JS, Bachowski S, Kolaja KL, Jiang J, et al. The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect. 1998;106 Suppl 1:289–95.PubMedCrossRef

13.

Chae HZ, Robison K, Poole LB, Church G, Storz G, Rhee SG. Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. Proc Natl Acad Sci USA. 1994;91:7017–21.PubMedCrossRef

14.

Hofmann B, Hecht HJ, Flohe L. Peroxiredoxins. Biol Chem. 2002;383:347–64.PubMed

15.

Wood ZA, Schroder E, Robin Harris J, Poole LB. Structure, mechanism and regulation of peroxiredoxins. Trends Biochem Sci. 2003;28:32–40.PubMedCrossRef

16.

Song IS, Kim HK, Jeong SH, Lee SR, Kim N, Rhee BD, et al. Mitochondrial peroxiredoxin III is a potential target for cancer therapy. Int J Mol Sci. 2011;12:7163–85.PubMedCrossRef

17.

Karihtala P, Mantyniemi A, Kang SW, Kinnula VL, Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res. 2003;9:3418–24.PubMed

18.

Lehtonen ST, Svensk AM, Soini Y, Paakko P, Hirvikoski P, Kang SW, et al. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer. 2004;111:514–21.PubMedCrossRef

19.

Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol. 2006;175:1512–6.PubMedCrossRef

20.

Cha MK, Suh KH, Kim IH. Overexpression of peroxiredoxin I and thioredoxin1 in human breast carcinoma. J Exp Clin Cancer Res. 2009;28:93.PubMedCrossRef

21.

Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG, et al. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol. 2002;196:316–23.PubMedCrossRef

22.

Chung YM, Yoo YD, Park JK, Kim YT, Kim HJ. Increased expression of peroxiredoxin II confers resistance to cisplatin. Anticancer Res. 2001;21:1129–33.PubMed

23.

Zhang B, Su Y, Ai G, Wang Y, Wang T, Wang F. Involvement of peroxiredoxin I in protecting cells from radiation-induced death. J Radiat Res. 2005;46:305–12.PubMedCrossRef

24.

Choi JH, Kim TN, Kim S, Baek SH, Kim JH, Lee SR, et al. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res. 2002;22:3331–5.PubMed

25.

Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, Chae HZ. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 2001;21:2085–90.PubMed

26.

Nonn L, Berggren M, Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res. 2003;1:682–9.PubMed

27.

Chang TS, Cho CS, Park S, Yu S, Kang SW, Rhee SG. Peroxiredoxin III, a mitochondrion-specific peroxidase, regulates apoptotic signaling by mitochondria. J Biol Chem. 2004;279:41975–84.PubMedCrossRef

28.

Jurisicova A, Jurisica I, Kislinger T. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions. Expert Rev Proteomics. 2008;5:551–60.PubMedCrossRef

29.

Wonsey DR, Zeller KI, Dang CV. The c-Myc target gene PRDX3 is required for mitochondrial homeostasis and neoplastic transformation. Proc Natl Acad Sci USA. 2002;99:6649–54.PubMedCrossRef

30.

Li XQ, Zhang SL, Cai Z, Zhou Y, Ye TM, Chiu JF. Proteomic identification of tumor-associated protein in ovarian serous cystadenocarinoma. Cancer Lett. 2009;275:109–16.PubMedCrossRef

31.

Kim K, Yu M, Han S, Oh I, Choi YJ, Kim S, et al. Expression of human peroxiredoxin isoforms in response to cervical carcinogenesis. Oncol Rep. 2009;21:1391–6.PubMed

32.

Chua PJ, Lee EH, Yu Y, Yip GW, Tan PH, Bay BH. Silencing the peroxiredoxin III gene inhibits cell proliferation in breast cancer. Int J Oncol. 2010;36:359–64.PubMed

33.

Su DM, Zhang Q, Wang X, He P, Zhu YJ, Zhao J, et al. Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy. Mol Cancer Ther. 2009;8:1292–304.PubMedCrossRef

34.

Jarvela S, Rantala I, Rodriguez A, Kallio H, Parkkila S, Kinnula VL, et al. Specific expression profile and prognostic significance of peroxiredoxins in grade II-IV astrocytic brain tumors. BMC Cancer. 2010;10:104.PubMedCrossRef

35.

Park JH, Kim YS, Lee HL, Shim JY, Lee KS, Oh YJ, et al. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology. 2006;11:269–75.PubMedCrossRef

36.

Vivas-Mejia PE, Ozpolat B, Chen X, Lopez-Berestein G. Downregulation of the c-Myc target gene, peroxiredoxin III, contributes to arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Int J Cancer. 2009;125:264–75.PubMedCrossRef

37.

Liu X, Feng R, Du L. The role of enoyl-CoA hydratase short chain 1 and peroxiredoxin 3 in PP2-induced apoptosis in human breast cancer MCF-7 cells. FEBS Lett. 2010;584:3185–92.PubMedCrossRef

38.

Pak JH, Choi WH, Lee HM, Joo WD, Kim JH, Kim YT, et al. Peroxiredoxin 6 overexpression attenuates cisplatin-induced apoptosis in human ovarian cancer cells. Cancer Invest. 2011;29:21–8.PubMedCrossRef

Titel: Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer
verfasst von: Xin-yan Wang
Hai-jiao Wang
Xiu-qin Li
Publikationsdatum: 01.08.2013
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 4/2013
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-0769-0

Neu im Fachgebiet Onkologie

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Peroxiredoxin III protein expression is associated with platinum resistance in epithelial ovarian cancer

Abstract

Neu im Fachgebiet Onkologie

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2013

Clinical and prognostic significance of Yes-associated protein in colorectal cancer

Prognostic value of survivin expression in breast cancer patients: a meta-analysis

CYP2E1 T7632A and 9-bp insertion polymorphisms and colorectal cancer risk: a meta-analysis based on 4,592 cases and 5,918 controls

The role of low-molecular-weight protein tyrosine phosphatase (LMW-PTP ACP1) in oncogenesis

Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme

Scytonemin inhibits cell proliferation and arrests cell cycle through downregulating Plk1 activity in multiple myeloma cells

Neu im Fachgebiet Onkologie

CAR-M-Zellen: Warten auf das große Fressen

Blutdrucksenkung könnte Uterusmyome verhindern

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Update Onkologie